您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Triamterene(SKF8542)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Triamterene(SKF8542)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Triamterene(SKF8542)图片
CAS NO:396-01-0
规格:≥98%
包装与价格:
包装价格(元)
250mg电议
500mg电议
1g电议
2g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)253.26
FormulaC12H11N7
CAS No.396-01-0
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 20 mg/mL (79 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)0.5% CMC Na+1% Tween 80: 30 mg/mL
SynonymsSKF-8542; BRN 0266723; SKF 8542; BRN0266723; SKF8542; BRN-0266723; Triamterene; Diucelpin; Diurene
实验参考方法
In Vitro

In vitro activity: Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. Triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.

In Vivo4'-hydroxylation of triamterene in humans appears to be mediated exclusively by CYP1A2. Inhibition or induction of CYP1A2 will change the time course of both triamterene and its active phase-II metabolite.
Animal model
Formulation & Dosage
References

Mol Pharmacol. 2003 Oct;64(4):848-56; Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.